Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Total Liabilities (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 5 years of Total Liabilities data on record, last reported at $98.0 million in Q4 2025.

  • For Q4 2025, Total Liabilities fell 94.07% year-over-year to $98.0 million; the TTM value through Dec 2025 reached $98.0 million, down 94.07%, while the annual FY2025 figure was $98.0 million, 94.07% down from the prior year.
  • Total Liabilities reached $98.0 million in Q4 2025 per INDV's latest filing, down from $1.6 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $1.9 billion in Q4 2023 and bottomed at $15.0 million in Q4 2022.
  • Average Total Liabilities over 5 years is $757.7 million, with a median of $285.0 million recorded in 2025.
  • Peak YoY movement for Total Liabilities: plummeted 99.12% in 2022, then skyrocketed 12846.67% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $1.7 billion in 2021, then tumbled by 99.12% to $15.0 million in 2022, then surged by 12846.67% to $1.9 billion in 2023, then decreased by 14.93% to $1.7 billion in 2024, then plummeted by 94.07% to $98.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $98.0 million in Q4 2025, $1.6 billion in Q3 2025, and $257.0 million in Q2 2025.